From June 18 to 20, 2016, the " second pharmaceutical frontier summit forum" jointly sponsored by the Editorial Committee of " Pharmaceutical Progress", the Chinese Pharmaceutical University and the Chinese Pharmaceutical Society was successfully held at the Liverpool international conference center in Suzhou. The theme of the meeting was " China's new drug research and development under the perspective of globalization: strategies ". The aim of the meeting was to build an innovative platform for the research, production, research and promotion of new drug research and development, and to discuss the internationalization path of new drug research and development and to dream about the long-term future of Chinese medicine under the guidance of national pharmaceutical science and technology and industrial demand.

Dr. Lu Xianping, the president of CHIPSCREEN BIOSCIENCES, was invited to attend the meeting and gave a wonderful report on " retrospect and prospect research: tortuous course of new drug development in diabetes" in the keynote forum " outlook: new trends in innovation-driven drug research and development". Dr. Lu reviewed the tortuous course of research and development of new medicines for diabetes and introduced the frontier developments in this field.

Dr. Lu pointed out that the treatment of diabetes has brought about rising social costs. Currently, there are six major types of therapeutic drugs in the market (sulfonylurea, GLP-1, DDP-4 inhibitors, TZD, SGLT-2 inhibitors, metformin), but there are different adverse reactions. Especially in the treatment of type 2 diabetes, there are many challenges, such as improving patients' treatment compliance, reducing cardiovascular complications, and continuously controlling glycated hemoglobin. The post-stroke insulin resistance intervention study (IRIS) mainly explores whether pioglitazone can reduce the incidence of end-point events ( such as stroke and myocardial infarction ) when applied to patients with ischemic stroke or transient cerebral ischemia (TIA) accompanied by severe insulin resistance. The results show that the drug is effective, has no obvious unexpected risk, and the risk is controllable. At present, the mechanism of how it reduces cardiovascular events has not been clarified, but the experimental results will encourage people to further explore accurate medical treatment of vascular diseases.

There are others attending the meeting including Academician Sang Guowei, the chairman of the Chinese Pharmaceutical Society; Academician Chen Kaixian, the vice-president of the National Science and Technology Major Special " Major New Drug Discovery" Technology and the head of Expert Group on Chemical Liability; Academician Wang Guangji, the general expert of the National Major Special ( major new drug discovery ); and dozens of experts in the field of new drug research and development and the chairman of the board of directors of pharmaceutical enterprises.